Thought people might be interested in the interim results.
The company hasn’t detailed how much it would charge for the treatment, but Kathiresan has said it will be more affordable than some of the gene therapies with million-dollar price tags. He says the PCSK9 base editor could one day be used to treat people who don’t have FH but have early heart disease. It could even be given widely to older adults to ward off disease. “Down the road, maybe you turn 50, and this is what you get and it prolongs your life,” he says. “That’s the ultimate vision.”
In the meanwhile, statins, bempedoic acid, PCSK9 inhibitors and ezetimibe will have to do.